Notable Labs, Ltd. (NASDAQ: NTBL) had its price target lowered by analysts at Chardan Capital from $9.00 to $7.00. They now have a "buy" rating on the stock.
Notable Labs, Ltd. - Ordinary Shares (NTBL)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
NTBL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTBL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTBL alerts
High impacting Notable Labs, Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NTBL
News
- Notable Labs, Ltd. (NASDAQ: NTBL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.MarketBeat
- Notable Labs Reports 2023 Financial Results and Provides a Business UpdateGlobeNewswire
- Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024GlobeNewswire
- Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the PlatformGlobeNewswire
- Notable Labs to Present Two Posters at AACR 2024 on PPMP PlatformGlobeNewswire
NTBL
Sec Filings
- 4/19/24 - Form S-8
- 4/12/24 - Form 8-K
- 4/11/24 - Form 10-K
- NTBL's page on the SEC website